Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-07
1998-01-20
Lambkin, Deborah
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514445, 514448, 514342, 549 68, 549 61, 549 62, 549 71, 549 66, 549 59, 549 75, 549 65, 5462804, A61K 3138, A61K 3144, C07D33342, C07D40912
Patent
active
057101736
ABSTRACT:
The present invention relates to molecules capable of modulating tyrosine signal transduction to prevent and treat cell proliferative disorders or cell differentiation disorders associated with particular tyrosine kinases by inhibiting one or more abnormal tyrosine kinase activities.
REFERENCES:
patent: 3013018 (1961-12-01), Dickinson, Jr.
patent: 3379677 (1968-04-01), Dressler et al.
patent: 3404160 (1968-10-01), Strobel et al.
patent: 3478020 (1969-11-01), Zienty et al.
patent: 3729500 (1973-04-01), Cragoe, Jr.
patent: 3790594 (1974-02-01), Meiser et al.
patent: 4923994 (1990-05-01), Wollweber
patent: 4933339 (1990-06-01), Sharma
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
Aaronson, S. A. (1991). Growth factors and cancer. Science 254, 1146-1153.
Arvidsson, A.-K., et al. (1994). Tyr-716 in the platelet-derived growth factor b-receptor kinase insert is involved in GRB2 binding and ras activation. Molecular and Cellular Biology 14, 6715-6726.
Baserga, R. (1995). The insulin-like growth factor I receptor: a key to tumor growth? Cancer Research 55, 249-252.
Bisbee, C. (1995). Scatter factor/hepatocyte growth factor gene deletion leads to death in knockout mice. BioWorld Today 24 Feb. 1995, 2.
Carraway, L. K., et al. (1994). The erbB3 Gene Product Is a Receptor for Heregulin. The Journal of Biological Chemistry 269, 14303-14306.
Carraway, K. L., and Cantley, L. C. (1994). A New Acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling. Cell 78, 5-8.
Claesson-Welsh, L. (1994). Signal transduction by the PDGF receptors. Progress in Growth Factor Research 5, 37-54.
Cullen, K. J., Yee, D., and Rosen, N. (1991). Insulinlike Growth Factors in Human Malignancy. Cancer Investigation 9, 443-454.
Dati, C., Antoniotti, S., Taverna, D., Perroteau, I., and De Bortoli, M. (1990). Inhibition of c-erB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 5, 1001-1006.
Decker, T., and Lohmann-Matthes, M.-L. (1988). A quick and simple method for quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. of Imm. Methods 15, 61-69.
de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., and Williams, L. T. (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989-991.
Dougall, W. C., Qian, X., Peterson, N. C., Miller, M. J., Samanta, A., and Greene, M. I. (1994). The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9, 2109-2123.
Fendly, B. M. (1990). Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2
eu gene product. Cancer Research 50, 1550-1558.
Ferrara, N., and Henzel, W. J. (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochemical and Biophysical Research Communications 161, 851-858.
Fingl, E., and Woodbury, D. M. (1975). The Pharmacological Basis of Therapeutics Chapter I, 1-46.
Floege, J., Eng, E., Young, B. A., and Johnson, R. J. (1993). Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. Kidney International 43, S-47 --S-54.
Folkman, J. (1971). Tumor Angiogenesis: therapeutic implications. The New England Journal of Medicine v. 285, 18 Nov. 1971, 1182-1186.
Folkman, J. (1990). What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute 82, 4-6.
Folkman, J., and Shing, Y. (1992). Angiogenesis. The Journal of Biological Chemistry 267, 10931-10934.
Fry, M. J., Panayotou, G., Booker, G. W., and Waterfield, M. D. (1993). New insights into protein-tyrosine kinase receptor signaling complexes. Protein Science 2, 1785-1797.
Giordano, S., Di Renzo, M. F., Olivero, M., Mondino, A., Zhen, Z., Medico, E., and Comoglio, P. M. (1992). The c-met/HGF receptor in human tumours. European Journal of Cancer Prevention 1, 45-49.
Gottardis, M. M., Robinson, S. P., and Jordan, C. V. (1988). Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: A model to study the tumoristatic action of tamoxifen. J. Steriod Biochem. 30, 311-314.
Harris, J. R., Lippman, M. E., Veronesi, U., and Willett, W. (1992). Breast Cancer. New England Journal of Medicine 327, 319-328.
Honegger, A. M., et al. (1987). Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 51, 199-209.
Houck, K. A., et al. (1992). Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. The Journal of Biological Chemistry 267, 26031-26037.
Hu, P., et al. (1992). Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derive Growth Factor Receptors. Molecular and Cellular Biology 12, 981-990.
Jellinek, D., Green, L. S., and Janjic, N. (1994). Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. Biochemistry 33, 10450-10456.
Jucker, M., et al. (1994). The Met/Hepatocyte Growth Factor Receptor (HGFR) Gene is Overexpressed in Some Cases of Human Leukemia and Lymphoma. Leukemia Research 18, 7-16.
Kashishian, A., Kazlauskas, A., and Cooper, J. A. (1992). Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo. The EMBO J 11, 1373-1382.
Kashishian, A., and Cooper, J. A. (1993). Phosphorylation sites at the C-terminus of the platelet-derived growth factor receptor bind phospholipase Cg1. Molecular Biology of the Cell 4, 49-57.
Kazlauskas, A., et al. (1993). The 64-kDa protein that associates with the platelet-derived growth factor receptor b subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp. Proc. Natl. Acad. Sci. USA 90, 6939-6942.
Kendall, R. L., and Thomas, K. A. (1993). Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc.Natl.Acad.Sci. 90, 10705-10709.
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844.
Kinsella, J. L., Grant, D. S., Weeks, B. S., and Kleinman, H. K. (1992). Protein kinase C regulates endothelial cell tube formation on basement membrane matrix, matrigel. Experimental Cell Research 199, 56-62.
Klagsbrun, M., and Soker, S. (1993). VEGF/VPF: the angiogenesis factor found? Current Biology 3, 699-702.
Korzseniewski, C., and Callewaert, D. M. (1983). An enzyme-release assay for natural cytotoxicity. Journal of Immunological Methods 64, 313-320.
Krywicki, and Yee, D. (1992). The insulin-like growth factor family of ligands, receptors, and binding proteins. Breast Cancer Research and Treatment 22, 7-19.
Mariani, M., et al. (1994). Inhibition of angiogenesis by PCE26806, a potent tyrosine kinase inhibitor. Proceedings of the American Association for Cancer Research 35, 381.
Marshall, E. (1993). Search for a killer: focus shifts from fat to hormones. Science 259, 618-621.
Millauer, B., et al. (1993). High Affinity VEGF Binding and Developmental Expression Suggest FLK-1 as a Major Regulator of Vasculogenesis and Angiogenesis. Cell 72, 835-846.
Mosmann, T. (1983). Rapid Colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 65, 55-63.
Natali, P. G., et al. (1993). Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br. J. Cancer 68, 746-750.
Nishimura, R., et al. (1993). Two Signaling Molecules Share a Phosphotyrosine-Containing Binding Site in the Platelet-Derived Growth Factor Receptor. Molecular and Cellular Biology 13, 6889-6896.
Osborne, C. K., Hobbs,
McMahon Gerald
Nematalla Asaad S.
Tang Peng Cho
Lambkin Deborah
Sugen Inc.
LandOfFree
Thienyl compounds for inhibition of cell proliferative disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thienyl compounds for inhibition of cell proliferative disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thienyl compounds for inhibition of cell proliferative disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-725738